Section
The ESTIVAL trial investigated transcutaneous auricular vagus nerve stimulation (taVNS) for erosive hand osteoarthritis. While the primary pain reduction endpoint was not met, the therapy proved safe and showed potential efficacy in patient
Interim data from the multicentre REVEAL study demonstrate that anifrolumab facilitates rapid disease control in real-world SLE patients, with 66% achieving low disease activity within six months, particularly in those with mucocutaneous an
A phase 4 RCT in Brazil confirms that the recombinant zoster vaccine does not increase the risk of disease flares in patients with autoimmune rheumatic diseases compared to placebo, maintaining a favorable safety profile even under immunosu
This article explores the multi-faceted health benefits of tart cherry juice, from its potent anti-inflammatory properties to its role in enhancing sleep and cardiovascular health, supported by the latest clinical research.
A recent decision analytical model identifies duloxetine 120 mg as the most cost-effective treatment for moderate-to-severe fibromyalgia, providing superior clinical outcomes at a marginal cost increase compared to amitriptyline, particular
A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor
The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, high
The RESTORE trial’s 3-year follow-up reveals that Cognitive Functional Therapy (CFT) provides sustained reductions in disability and pain for chronic low back pain compared to usual care, offering a transformative, evidence-based appr
The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi
A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a
A groundbreaking clinical trial explores whether injecting steroids into the knee’s infrapatellar fat pad can alleviate pain and protect cartilage. While primary pain targets weren’t met, the secondary findings offer a fascinating gli
Three cases of pentosan polysulfate maculopathy occurred after subcutaneous administration for arthritis at much lower cumulative doses than oral use, highlighting retinal toxicity risk and need for early detection.
AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w
The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with n
The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu
The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus
A 102-participant pilot RCT in Germany found that a self-guided digital psychological intervention produced clinically meaningful reductions in psychological distress and modest improvements in quality of life at 3 months in people with inf
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesi
